Introduction
PAD, peripheral artery disease
PAD, EVENTS, PERIPHERAL ARTERY DISEASE
Globally, more than 200 million people suffer from peripheral artery disease (PAD), and its prevalence is rising with the increasing aging populationThe role of medical therapy after revascularization is especially essential for symptomatic PAD patients who have undergone revascularization either by endovascular intervention or open surgery. According to a recent analysis of administrative data from the United States, there has been a rapid increase in major adverse limb events (MALE) during the first year after PAD revascularization, with 12.9% of patients readministered for MALE at a median of 4 months post-procedureSarpogrelate is a selective 5-hydroxytryptamine (5-HT) 2A receptor antagonist that inhibits 5-HT-induced platelet aggregationTherefore, in the current SAFE (Sarpogrelate Anplone in Femoropopliteal artery intervention Efficacy) study we performed a clinical trial to assess the efficacy and safety of dual antiplatlet therapy (DAPT) with sarpogrelate and aspirin compared to clopidogrel and aspirin in PAD patients during the early periods following endovascular revascularization.